These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25548500)

  • 1. Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis.
    Liu H; Zhang QD; Li ZH; Zhang QQ; Lu LG
    World J Gastroenterol; 2014 Dec; 20(47):18001-12. PubMed ID: 25548500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis.
    Yang R; Wang B; Chen YJ; Li HB; Hu JB; Zou SQ
    Anticancer Drugs; 2013 Sep; 24(8):871-7. PubMed ID: 23799294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y; Sun J; Jiang Z; Zhang L; Liu G
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
    Jin SF; Fan ZK; Pan L; Jin LM
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
    Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
    Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
    Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
    Novarino AM; Satolli MA; Chiappino I; Giacobino A; Napoletano R; Ceccarelli M; Ciccone G; Schena M; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2013 Oct; 36(5):466-71. PubMed ID: 22781390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy and targeted therapy for advanced biliary tract cancers: an umbrella review.
    Wang Y; Wen N; Wang S; Nie G; Tian Y; Lu J; Li B
    BMC Cancer; 2023 Apr; 23(1):378. PubMed ID: 37098481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
    Kanai M; Yoshimura K; Tsumura T; Asada M; Suzuki C; Niimi M; Matsumoto S; Nishimura T; Nitta T; Yasuchika K; Taura K; Mori Y; Hamada A; Inoue N; Tada S; Yanagihara K; Yazumi S; Osaki Y; Chiba T; Ikai I; Fukushima M; Uemoto S; Hatano E
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1429-34. PubMed ID: 20811895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
    Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
    Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of gemcitabine and cisplatin combination chemotherapy versus gemcitabine alone for pancreatic cancer.
    Huang D; Fang J; Luo G
    J Cancer Res Ther; 2016 Oct; 12(Supplement):104-108. PubMed ID: 27721265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine alone or in combination with Cisplatin for advanced biliary tract carcinomas: an overview of clinical evidence.
    Sun TT; Wang JL; Fang JY
    Asian Pac J Cancer Prev; 2013; 14(2):877-83. PubMed ID: 23621255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.
    Fiteni F; Nguyen T; Vernerey D; Paillard MJ; Kim S; Demarchi M; Fein F; Borg C; Bonnetain F; Pivot X
    Cancer Med; 2014 Dec; 3(6):1502-11. PubMed ID: 25111859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials.
    Zhuang X; Xiao YP; Tan LH; Wang LT; Cao Q; Qu GF; Xiao S; Duan HX
    J Huazhong Univ Sci Technolog Med Sci; 2017 Apr; 37(2):172-178. PubMed ID: 28397047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.
    Chung MJ; Kim YJ; Park JY; Bang S; Song SY; Chung JB; Park SW
    Chemotherapy; 2011; 57(3):236-43. PubMed ID: 21597288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
    Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K
    Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.